Pfizer Quarterly Balance Sheet
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
Pfizer financial position
As of Jun 28, 2026, Pfizer reported total assets of $201.13 billion, down 2.4% from a year earlier against total liabilities of $115.64 billion. Shareholders' equity stood at $85.19 billion, or 42.4% of assets. The company held $976.0 million in cash and equivalents against $63.19 billion of debt, a net debt position of $62.22 billion.
The current ratio (current assets divided by current liabilities) was 1.27, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.74.
Summary generated from market data by MetaCap's automated system. Methodology
Pfizer balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-28 | Q1 20262026-03-29 | Q4 20252025-12-31 | Q3 20252025-09-28 | Q2 20252025-06-29 | Q1 20252025-03-30 | Q4 20242024-12-31 | Q3 20242024-09-29 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-10-01 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 976.00M | 1.70B | 1.14B | 1.34B | 1.64B | 1.43B | 1.04B | 1.09B | 1.05B | 719.00M | 2.85B | 3.15B |
| Short-Term Investments | 7.28B | 8.19B | 9.18B | 10.12B | 9.53B | 13.95B | 10.88B | 6.85B | 4.40B | 8.22B | 4.40B | 26.25B |
| Receivables | 12.49B | 12.59B | 11.87B | 14.26B | 12.08B | 11.85B | 11.46B | 14.45B | 11.39B | 10.99B | 11.57B | 11.09B |
| Inventory | 9.95B | 10.67B | 10.65B | 11.47B | 11.67B | 10.85B | 10.85B | 11.72B | 11.45B | 10.89B | 10.19B | 10.20B |
| Total Current Assets | 41.36B | 42.82B | 42.90B | 46.92B | 43.70B | 45.86B | 50.36B | 43.22B | 37.83B | 42.41B | 43.33B | 74.01B |
| Property, Plant & Equipment | 19.03B | 19.40B | 19.32B | 18.88B | 18.78B | 18.35B | 18.39B | 18.54B | 18.96B | 18.80B | 18.94B | 17.86B |
| Goodwill | 71.42B | 71.41B | 71.26B | 69.10B | 69.00B | 68.44B | 68.53B | 68.57B | 68.44B | 69.30B | 67.78B | 51.53B |
| Intangible Assets | 47.05B | 52.56B | 53.73B | 51.32B | 52.70B | 53.98B | 55.41B | 59.99B | 61.24B | 62.83B | 64.90B | 40.22B |
| Long-Term Investments | 0 | 0 | 1.00M | 1.00M | 2.12B | 2.01B | 2.23B | 10.76B | 11.15B | 11.61B | 15.37B | 14.24B |
| Total Assets | 201.13B | 207.62B | 208.16B | 208.73B | 206.09B | 208.03B | 213.40B | 219.48B | 216.19B | 221.09B | 226.50B | 215.02B |
| Accounts Payable | 4.58B | 4.51B | 5.24B | 5.02B | 5.17B | 5.24B | 5.63B | 5.31B | 5.11B | 5.59B | 6.71B | 5.34B |
| Short-Term Debt | 2.70B | 3.89B | 3.15B | 4.30B | 4.29B | 4.47B | 6.95B | 9.70B | 11.94B | 8.23B | 10.35B | 2.55B |
| Total Current Liabilities | 32.65B | 34.35B | 36.98B | 36.60B | 37.73B | 36.45B | 42.99B | 43.21B | 43.82B | 40.50B | 47.79B | 31.14B |
| Long-Term Debt | 60.49B | 60.56B | 61.64B | 57.41B | 57.50B | 57.64B | 57.41B | 58.00B | 57.51B | 61.31B | 61.54B | 61.05B |
| Total Liabilities | 115.64B | 117.21B | 121.39B | 115.64B | 117.08B | 117.39B | 124.90B | 126.92B | 128.22B | 128.54B | 137.21B | 117.82B |
| Shareholders' Equity | 85.19B | 90.10B | 86.48B | 92.80B | 88.69B | 90.34B | 88.20B | 92.29B | 87.70B | 92.28B | 89.01B | 96.93B |
| Retained Earnings | 112.09B | 117.24B | 114.61B | 121.15B | 117.61B | 119.59B | 116.72B | 121.06B | 116.60B | 121.32B | 118.35B | 126.41B |
| Total Debt | 63.19B | 64.45B | 64.80B | 61.71B | 61.80B | 62.11B | 64.35B | 67.70B | 69.45B | 69.54B | 71.89B | 63.60B |
| Net Cash (Debt) | -54.94B | -54.56B | -54.47B | -50.25B | -50.63B | -46.73B | -52.43B | -59.76B | -64.00B | -60.60B | -64.64B | -34.20B |
This table shows 12 quarterly periods of Pfizer's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow PFE's reporting calendar. What is a balance sheet?